Advances in Vaccine Immunology: Mechanisms of Immune Activation and Long-Term Protection

Esha Javed[1], Aleeza Ijaz[1], Malika[1], Saneha Parvaiz[1], Fatima Kamran[2] and Moiza Noor[3*]

1. Department of Physiology, Faculty of Life Sciences, Government College University Faisalabad
2. Department of Zoology, Faculty of Sciences, University of Agriculture Faisalabad
3. Department of Medical Laboratory Technology, Faculty of Medical Sciences, Government College University Faisalabad

*Corresponding Author: **moizanoor704@gmail.com**

ABSTRACT

The field of vaccine immunology has greatly improved infectious disease prevention and control by providing insights into how vaccines induce protective immunity. Vaccines work by imitating natural infections, thus priming the innate and adaptive immune responses without disease. This includes the recognition, processing of antigens by antigen-presenting cells, and activation of T and B lymphocytes, which results in the production of pathogen-specific antibodies and the establishment of immune memory. Contemporary vaccine technologies, such as live attenuated, inactivated, subunit, viral vector, and mRNA vaccines, have varying immunologic mechanisms of action and associated benefits and challenges. Adjuvants also play a crucial role in enhancing vaccine responses through activation of the innate immune system and enhanced antigen presentation. But immune responses can vary widely following vaccination due to age, genetic background, nutrition, and co-infections. The future of vaccines lies in new technologies, such as nucleic acid–based vaccines and novel adjuvants, which allow for rapid response, targeted immune responses, and protection against diverse pathogens. This review emphasizes the critical mechanisms of immune activation, factors contributing to long-term protection, and the future of vaccine development for global health.

Keywords: Vaccine Immunology, Immune Memory, Antigen Presentation, mRNA Vaccines, Adjuvants

To cite this article: Javed E, A Ijaz, Malika, S Parvaiz, F Kamran & M Noor. Advances in Vaccine Immunology: Mechanisms of Immune Activation and Long-Term Protection. Biological Times. 2026. April 5(4): 18-20.

Introduction

Vaccines are biological agents that stimulate the immune system to develop protection against specific infectious diseases without causing illness [1]. The scientific and pharmaceutical enterprises have developed vaccines to protect humans against dozens of diseases. National immunization programs in the United States and beyond have introduced and sustained the delivery of many of these interventions [2]. Vaccines protect against several acute infectious diseases and the long-term complications of these infections, which range from congenital rubella syndrome to Hepatitis B and human papillomavirus-related cancers. Much of this progress was accomplished over the past 50 years in the developed world, but progress often lagged by decades in resource-poor settings. Although numerous challenges continue to threaten these successes, the scorecard currently shows science and immunization programs winning the contest against the vaccine-preventable diseases they target [3]. Before the development and wide use of human vaccines, few people survived childhood without experiencing a litany of diseases, including measles, mumps, rubella, chickenpox, whooping cough, and rotavirus diarrhea [4]. By 1955, on the tenth anniversary of President Roosevelt's death, investigators announced to a packed auditorium the results of a nationwide clinical trial of Salk's inactivated polio vaccine among schoolchildren, an announcement broadcast live across the country [5].

The U.S. immunization program can trace its origins to the major vaccination campaigns that followed, first against polio and then against measles and rubella, once vaccines against those diseases were developed during the 1960s. Poliomyelitis became rare in the U.S. within years of the initial vaccine campaigns and was certified to have been eliminated from the Americas by 1994 [6]. Variability in long-term immunity remains an important gap in scientific knowledge, as individuals show significant differences in how durable and effective their immune responses are after infection or vaccination [7]. This heterogeneity is influenced by factors such as genetic background, age, nutritional status, and overall health, yet precise predictors of who will develop strong and lasting immunity are still lacking. Long-term protection depends on immune memory, particularly memory B cells and T cells, but the exact contribution and persistence of each component across different diseases is not fully understood [8]. The duration of immunity also varies widely, with some infections providing lifelong protection while others result in only short-term immunity, and the mechanisms behind this difference remain unclear. In addition, the evolution of pathogens through mutations can reduce the effectiveness of existing immune memory, making it difficult to predict how well immunity will adapt over time [9].

Overview of the Immune System in Vaccination:

Vaccines induce immune responses that are highly complex and include orchestrated actions of a wide range of immune cells in both innate and adaptive immune systems. Ultimately, most current vaccines protect pathogen-specific antibodies that target epitopes on pathogens or their toxic components [10]. Antibodies are exclusively produced by a subset of B-lymphocytes (B-cells) called plasma cells. The process of antibody production begins with vaccine antigens reaching the draining lymph nodes from the injection site, where they are captured by specialized macrophages in the subcapsular region and then transported to the B-cell zone (follicles). Here, B-cells are activated, and activated B-cells migrate toward the border region between B-cell follicles and the T-cell zone (called the marginal zone) [11].

Innate immunity is the body's first line of defense against infections and injury. Innate immunity is nonspecific and responds quickly to microbial invaders or cellular damage [12]. A crucial aspect of the innate immune system is the use of pattern recognition receptors (PRRs). PRRs are specialized proteins expressed on the surface or inside immune cells, and they serve as the immune system's sensors. These receptors are responsible for recognizing common molecular patterns present on pathogens (PAMPs) or released by damaged or dying cells (DAMPs). By detecting these patterns, PRRs trigger immune responses to eliminate threats or repair tissue damage [13]. Cytokines play an important role in inflammation and the subsequent immune response. Different cytokines can have positive and negative effects on cell function, playing a role not only in the immune response and inflammation but also in reproduction, trauma, and disease formation (cancer, asthma, heart and endocrine diseases, and others). The nature of the immune response depends on the nature of the cytokines [14]. Adaptive immunity, which is highly specific and memory-based, is antigen-dependent and involves a time lag between antigen exposure and the maximal response. The hallmark of adaptive immunity is its memory capacity in generating a faster and more effective immune response [15]. The cells of the adaptive immune system are T-lymphocytes and B-lymphocytes, which are highly motile. Adaptive immune responses may also respond to indirect stimuli from mucosal antigen-presenting cells (APCs) that migrate to secondary organs. Lymphocytes can then travel to many sites in the body where they perform effector functions [16]. CD4+T cells play an important role in lung disease, showing a high degree of heterogeneity and plasticity, and are regulated in response to stimulation with cognate antigens bound to MHC class II molecules. Thus, the antigen-presenting cell type and the additional signals it provides directly affect CD4+T cell programming and its downstream effector mechanisms. The expression of MHC II is mainly limited to professional APCs, but epithelial cells and fibroblasts can also express MHC II [17]. To present antigens to

CD8+T or CD4+T cells, APCs must express either MHC I or MHC II, respectively. It is necessary for cells to have the capability of increasing the expression of co-stimulatory proteins like B7, which interacts with CD28 found on the outer layer of T cells [18]. T cell activation depends on antigen presentation by major histocompatibility complex (MHC) molecules on professional antigen-presenting cells (pAPCs), costimulatory receptor interaction, and cytokines [19].

Antigen Recognition and Processing:

Vaccines initiate immune responses by introducing antigens into the body, which are recognized by antigen-presenting cells (APCs), including dendritic cells, macrophages, and B cells [20]. APCs capture the antigen and process it into smaller peptide fragments that can be presented on major histocompatibility complex (MHC) molecules [21]. Dendritic cells are the most potent APCs and play a critical role in linking innate and adaptive immunity. Once activated, they migrate to lymph nodes where they present antigens to naïve T cells, initiating a specific immune response [22]. This step is essential for developing long-term immune memory [23].

Adjuvants are substances added to vaccines to enhance the body's immune response to an antigen. Common adjuvants include alum, MF59, and AS03, each functioning through different mechanisms. Alum works by forming a depot effect and promoting antigen uptake by immune cells, leading to strong antibody responses [24, 25, 26]. MF59 enhances recruitment of immune cells to the injection site and improves antigen presentation. AS03 stimulates innate immune pathways and increases cytokine production, thereby boosting both cellular and humoral immunity [27, 28]. Adjuvants also help reduce the amount of antigen required and improve vaccine effectiveness, especially in populations with weaker immune responses, such as the elderly [29].

Vaccines activate both cellular and humoral branches of the immune system. T helper (CD4+) cells are activated when antigens are presented via MHC-II molecules, and they release cytokines that regulate immune responses [30]. Cytotoxic T cells (CD8+) are activated when antigens are presented through MHC-I molecules, leading to the destruction of infected cells [31]. This is particularly important for viral infections [32]. B cells are responsible for antibody production. Upon activation, they differentiate into plasma cells and produce antibodies that neutralize pathogens [33]. Class switching allows B cells to produce different types of antibodies, such as IgG, IgA, and IgE, improving the quality and durability of the immune response [34][55].

Types of Vaccines and Their Immunological Mechanisms:

Live attenuated vaccines contain weakened forms of pathogens that can replicate without causing disease. These vaccines closely mimic natural infection and induce strong and long-lasting cellular and humoral immunity. However, they are not suitable for immunocompromised individuals due to safety concerns [35, 36]. Inactivated vaccines contain killed pathogens that cannot replicate. They are safer than live vaccines but primarily induce humoral immune responses. These vaccines often require booster doses to maintain immunity [37, 38].

Subunit vaccines include only specific antigenic parts of a pathogen, such as proteins or polysaccharides. Recombinant vaccines use genetic engineering to produce these antigens. They are safer and have fewer side effects but may require adjuvants to enhance their immunogenicity [38, 40]. Viral vector vaccines use harmless viruses to deliver genetic material encoding a pathogen's antigen into host cells. This leads to endogenous antigen production and strong activation of both T cells and antibody responses. These vaccines are widely used in recent infectious disease control strategies [41, 42, 43]. mRNA vaccines deliver messenger RNA encoding a specific antigen into host cells, which then produce the antigen internally [44]. This mechanism stimulates both cellular and humoral immune responses effectively [45]. mRNA vaccines are highly adaptable and can be rapidly developed, making them crucial in pandemic responses. However, they require strict cold-chain storage and have stability limitations [46, 47].

Factors Affecting Vaccine-Induced Immunity:

Vaccine-induced immunity can vary significantly among individuals due to multiple biological and environmental factors [48]. Age is a major determinant, as infants have immature immune systems while elderly individuals experience immunosenescence, leading to weaker immune responses [49]. Genetic factors also influence vaccine responsiveness, as variations in genes related to immune function can affect antigen recognition and immune activation [50]. Nutritional status plays a critical role, as deficiencies in essential nutrients such as vitamins and minerals can impair immune responses [51].

Comorbidities, including chronic diseases like diabetes, obesity, and cardiovascular disorders, can reduce vaccine effectiveness by altering immune function [52, 56]. Environmental factors, such as exposure to pathogens, pollution, and lifestyle conditions, also impact immune responses and vaccine efficacy [53]. Understanding these factors is important for improving vaccine strategies and ensuring optimal protection across different populations [54].



Figure 1: This figure shows the key vaccine platforms and the different types of immunological approaches. It illustrates the various vaccines, such as inactivated, live attenuated, subunit, nucleic acid, viral vector, virus-like particle, and gene-deleted vaccines.

Future Perspective:

The future of advanced vaccine immunology is moving toward more precise, efficient, and versatile approaches that go beyond traditional disease prevention. At the same time, mRNA and other nucleic acid–based platforms are expected to dominate next-generation vaccine development because they allow rapid design, easy modification, and scalable production, with expanding applications in cancer immunotherapy and chronic infections. Researchers are also working toward universal vaccines that can provide broad protection against multiple strains of pathogens such as influenza and coronaviruses, reducing the need for frequent updates.

Advanced adjuvant systems play a crucial role in modern vaccine immunology by enhancing the magnitude, quality, and duration of immune responses, particularly in vaccines that use purified antigens, recombinant proteins, or nucleic acids. These advanced systems include immunostimulatory molecules such as Toll-like receptor (TLR) agonists (e.g., CpG oligodeoxynucleotides, saponin-based compounds like QS-21, and STING pathway activators), all of which trigger pattern recognition receptors and promote cytokine production, dendritic cell maturation, and enhanced antigen presentation.

Conclusion:

In summary, the field of vaccine immunology has advanced significantly, offering a wealth of knowledge on how immunity is activated and sustained. Vaccines successfully link innate and adaptive immunity by activating antigen recognition, cytokine production, and the activation of T and B cells, resulting in immune memory. The creation of a range of vaccine platforms, from classical live attenuated and killed vaccines to cutting-edge mRNA and viral vectors, has broadened the capacity to prevent numerous infectious diseases and their complications. However, there are still many challenges in explaining the variability of immune responses and achieving durable protection in a variable population. Age, genetics, nutrition, and health status still impact vaccine efficacy. And the ever-changing nature of pathogens continues to challenge long-term protection.

References

[1] Stinchfield P, Almeida K. Improving vaccination rates in the clinical setting. Pediatric Annals. 2023 Mar 1;52(3):e89-95.

[2] Roush SW, Murphy TV, Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. Jama. 2007 Nov 14;298(18):2155-63.

[3] Offit PA. The Cutter incident: how America's first polio vaccine led to the growing vaccine crisis. Yale University Press; 2007 Sep 18.

[4] Centers for Disease Control and Prevention (CDC. Certification of poliomyelitis eradication--the Americas, 1994. MMWR. Morbidity and mortality weekly report. 1994 Oct 7;43(39):720-2.

[5] de Quadros CA, Hersh BS, Olive JM, Andrus JK, da Silveira CM, Carrasco PA. Eradication of wild poliovirus from the Americas: acute flaccid paralysis surveillance, 1988–1995. The Journal of infectious diseases. 1997 Feb 1;175(Supplement_1):S37-42.

[6] Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity. 2010 Oct 29;33(4):451-63.

[7] Plotkin SA. Correlates of protection induced by vaccination. Clinical and vaccine immunology. 2010 Jul;17(7):1055-65.

[8] Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, Nakao C. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021 Feb 5;371(6529):eabf4063.

[9] Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nature immunology. 2011 Jun;12(6):509-17.

[10] Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu. Rev. Immunol.. 2005 Apr 23;23(1):515-48.

[11] Chung KP, Hsu CL, Fan LC, Huang Z, Bhatia D, Chen YJ, Hisata S, Cho SJ, Nakahira K, Imamura M, Choi ME. Mitofusins regulate lipid metabolism to mediate the development of lung fibrosis. Nature communications. 2019 Jul 29;10(1):3390.

[12] Casale TB, Kessler J, Romero FA. Safety of the intranasal toll-like receptor 4 agonist CRX-675 in allergic rhinitis. Annals of Allergy, Asthma & Immunology. 2006 Oct 1;97(4):454-6.

[13] Shirota H, Sano K, Hirasawa N, Terui T, Ohuchi K, Hattori T, Shirato K, Tamura G. Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. The Journal of Immunology. 2001 Jul;167(1):66-74.

[14] Tulic MK, Fiset PO, Christodoulopoulos P, Vaillancourt P, Desrosiers M, Lavigne F, Eiden J, Hamid Q. Amb a 1–immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. Journal of Allergy and Clinical Immunology. 2004 Feb 1;113(2):235-41.

[15] Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, Li H, Coffman R, Seyfert V, Eiden JJ, Broide D. Immunotherapy with a ragweed–Toll-like receptor 9 agonist vaccine for allergic rhinitis. New England Journal of Medicine. 2006 Oct 5;355(14):1445-55.

[16] Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell. 2006 Feb 24;124(4):849-63.

[17] Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cellular and molecular life sciences. 2008 Oct;65(20):3231-40.

[18] Schwarz TF. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Expert review of vaccines. 2008 Dec 1;7(10):1465-73.

[19] Kong NC, Beran J, Kee SA, Miguel JL, Sánchez C, Bayas JM, Vilella A, Calbo-Torrecillas F, de Novales EL, Srinivasa K, Stoffel M. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney international. 2008 Apr 1;73(7):856-62.

[20] Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nature immunology. 2011 Jun;12(6):509-17.

[21] Lucas C, Wong P, Klein J, Castro TB, Silva J, Sundaram M, Ellingson MK, Mao T, Oh JE, Israelow B, Takahashi T. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020 Aug 20;584(7821):463-9.

[22] Crotty S. Hybrid immunity. Science. 2021 Jun 25;372(6549):1392-3.

[23] Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021 Feb 18;184(4):861-80.

[24] Khandhar AP, Liang H, Simpson AC, Reed SG, Carter D, Fox CB, Orr MT. Physicochemical structure of a polyacrylic acid stabilized nanoparticle alum (nanoalum) adjuvant governs TH1 differentiation of CD4+ T cells. Nanoscale. 2020;12(4):2515-23.

[25] Garçon N, Segal L, Tavares F, Van Mechelen M. The safety evaluation of adjuvants during vaccine development: the AS04 experience. Vaccine. 2011 Jun 15;29(27):4453-9.

[26] Pulendran B, S. Arunachalam P, O'Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nature reviews Drug discovery. 2021 Jun;20(6):454-75.

[27] Sullivan SG, Khvorov A, Carolan L, Dowson L, Hadiprodjo AJ, Sánchez-Ovando S, Liu Y, Leung VK, Hodgson D, Blyth CC, Macnish M. Antibody responses against influenza A decline with successive years of annual influenza vaccination. npj Vaccines. 2025 Jan 17;10(1):11.

[28] Garçon N, Segal L, Tavares F, Van Mechelen M. The safety evaluation of adjuvants during vaccine development: the AS04 experience. Vaccine. 2011 Jun 15;29(27):4453-9.

[29] Poland GA, Ovsyannikova IG, Crooke SN, Kennedy RB. SARS-CoV-2 vaccine development: current status. InMayo Clinic Proceedings 2020 Oct 1 (Vol. 95, No. 10, pp. 2172-2188). Elsevier.

[30] Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021 Feb 18;184(4):861-80.

[31] Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L, Jadi RS, Marrama D. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020 Jun 25;181(7):1489-501.

[32] Moderbacher CR, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, Belanger S, Abbott RK, Kim C, Choi J, Kato Y. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020 Nov 12;183(4):996-1012.

[33] Victora GD, Nussenzweig MC. Germinal centers. Annual review of immunology. 2022 Apr 26;40:413-42.

[34] Mesin L, Schiepers A, Ersching J, Barbulescu A, Cavazzoni CB, Angelini A, Okada T, Kurosaki T, Victora GD. Restricted clonality and limited germinal center reentry characterize memory B cell reactivation by boosting. Cell. 2020 Jan 9;180(1):92-106.

[35] Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell. 2020 Oct 15;183(2):347-62.

[36] Plotkin SA. Recent updates on correlates of vaccine-induced protection. Frontiers in Immunology. 2023 Jan 27;13:1081107.

[37] Plotkin SA. Recent updates on correlates of vaccine-induced protection. Frontiers in Immunology. 2023 Jan 27;13:1081107.

[38] Poland GA, Ovsyannikova IG, Crooke SN, Kennedy RB. SARS-CoV-2 vaccine development: current status. InMayo Clinic Proceedings 2020 Oct 1 (Vol. 95, No. 10, pp. 2172-2188). Elsevier.

[39] Ward BJ, Gobeil P, Séguin A, Atkins J, Boulay I, Charbonneau PY, Couture M, D'Aoust MA, Dhaliwall J, Finkle C, Hager K. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. Nature medicine. 2021 Jun;27(6):1071-8.

[40] Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Lalloo U, Masilela MS, Moodley D, Hanley S, Fouche L. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B. 1.351 variant. New England Journal of Medicine. 2021 May 20;384(20):1899-909.

[41] Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, Liu J, Peter L, McMahan K, Tostanoski LH, He X. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020 Oct 22;586(7830):583-8.

[42] Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Van Dromme I, Spiessens B, Vingerhoets J. Final analysis of efficacy and safety of single-dose Ad26. COV2. S. New England Journal of Medicine. 2022 Mar 3;386(9):847-60.

[43] McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, Liu J, Peter L, Atyeo C, Zhu A, Bondzie EA. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021 Feb 25;590(7847):630-4.

[44] Pardi N, Weissman D. Development of vaccines and antivirals for combating viral pandemics. Nature biomedical engineering. 2020 Dec;4(12):1128-33.

[45] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England journal of medicine. 2021 Feb 4;384(5):403-16.

[46] Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, Brachtendorf S. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020 Oct 22;586(7830):594-9.

[47] Kleanthous H, Silverman JM, Makar KW, Yoon IK, Jackson N, Vaughn DW. Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. npj Vaccines. 2021 Oct 28;6(1):128.

[48] Zimmermann P, Curtis N. Bacterial meningitis in the absence of pleocytosis in children: a systematic review. The Pediatric Infectious Disease Journal. 2021 Jun 1;40(6):582-7.

[49] Jergović M, Coplen CP, Uhrlaub JL, Besselsen DG, Cheng S, Smithey MJ, Nikolich-Žugich J. Infection-induced type I interferons critically modulate the homeostasis and function of CD8+ naïve T cells. Nature communications. 2021 Sep 6;12(1):5303.

[50] Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. The Lancet. 2020 Nov 14;396(10262):1595-606.

[51] Calder PC. Nutrition and immunity: lessons for COVID-19. Nutrition & Diabetes. 2021 Jun 23;11(1):19.

[52] Painter MM, Mathew D, Goel RR, Apostolidis SA, Pattekar A, Kuthuru O, Baxter AE, Herati RS, Oldridge DA, Gouma S, Hicks P. Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity. 2021 Sep 14;54(9):2133-42.

[53] Rook GA, Bloomfield SF. Microbial exposures that establish immunoregulation are compatible with targeted hygiene. Journal of Allergy and Clinical Immunology. 2021 Jul 1;148(1):33-9.

[54] Lucas C, Klein J, Sundaram ME, Liu F, Wong P, Silva J, Mao T, Oh JE, Mohanty S, Huang J, Tokuyama M. Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nature medicine. 2021 Jul;27(7):1178-86.

[55] Afzal MA, Shahzadi N, Saadat S, Seemab R, Sajjad I, Tariq N, Ashraf SR, Tahir S, Kharl HA. CRISPR-Cas9 genome-editing technology: a transformative tool for curing human disorders. Journal of Medical & Health Sciences Review. 2025 Jul 29;2(3).

[56] Ashraf MA, MA Afzal, M Ijaz, A Arshad, MN Zafar, SM Ukkasha & I Zahid. Financial Impact of Nutrition on Non-Communicable Diseases in Hospital or Other Healthcare Settings. Biological Times. 2025. September 4(9): 20-21.